Compare ACR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACR | HURA |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | 4 | 22 |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 160.5M |
| IPO Year | N/A | N/A |
| Metric | ACR | HURA |
|---|---|---|
| Price | $17.62 | $2.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.50 | $9.50 |
| AVG Volume (30 Days) | 42.5K | ★ 731.4K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.61 | $0.41 |
| 52 Week High | $24.61 | $3.90 |
| Indicator | ACR | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 46.60 |
| Support Level | $17.34 | $2.14 |
| Resistance Level | $19.64 | $2.80 |
| Average True Range (ATR) | 0.46 | 0.19 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 57.89 | 31.00 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.